RQ3013

BIOLOGICAL3 trials

Sponsors

Walvax Biotechnology Co., Ltd., Affiliated Hospital of Yunnan University

Conditions

COVID-19

Phase 1

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Walvax Biotechnology Co., Ltd.COVID-19

Start: 2022-12-31End: 2023-06-30Target: 120Updated: 2022-11-18

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Walvax Biotechnology Co., Ltd.COVID-19

Start: 2022-07-31End: 2023-07-31Target: 120Updated: 2022-05-31

Unknown Phase

A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults

CompletedNCT05907044

Affiliated Hospital of Yunnan UniversityCOVID-19

Start: 2023-05-08End: 2023-11-23Updated: 2024-01-24